ArticleOncotarget2014
Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences.
Article in Oncotarget, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05660083 (Phase II Trial of Alpelisib With iNOS Inhibitor and Nab-paclitaxel in Patients With HER2 Negative Metastatic or Locally Advanced Metaplastic Breast Cancer), which is not on this map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Trial of Alpelisib With iNOS Inhibitor and Nab-paclitaxel in Patients With HER2 Negative Metastatic or Locally Advanced Metaplastic Breast Cancer (MpBC)
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between obesity with disease-free survival and overall survival in triple-negative breast cancer: A meta-analysis.Medicine · 2018Pooled it
- MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- Review
- Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1-HER3 signaling.Nature cancer · 2025Article
- Exploring the clinical potential of circulating LncRNAs in breast cancer: insights into primary signaling pathways and therapeutic interventions.Functional & integrative genomics · 2024Review
- GluOC promotes proliferation and metastasis of TNBC through the ROCK1 signaling pathway.Cancer cell international · 2024Article
- Molecular docking and MD simulation approach to identify potential phytochemical lead molecule against triple negative breast cancer.F1000Research · 2024Article
- BTB protein family and human breast cancer: signaling pathways and clinical progress.Journal of cancer research and clinical oncology · 2023Review
- Advances in immunotherapy for triple-negative breast cancer.Molecular cancer · 2023Review
- Overcoming the Challenges of Phytochemicals in Triple Negative Breast Cancer Therapy: The Path Forward.Plants (Basel, Switzerland) · 2023Review
- Predicting the Clinical Outcome of Triple-Negative Breast Cancer Based on the Gene Expression Characteristics of Necroptosis and Different Molecular Subtypes.Stem cells international · 2023Article
- Novel classes of immunotherapy for breast cancer.Breast cancer research and treatment · 2022Review
- Novel immune-related prognostic model and nomogram for breast cancer based on ssGSEA.Frontiers in genetics · 2022Article
- C(3)1-TAg in C57BL/6 J background as a model to study mammary tumor development.Histochemistry and cell biology · 2021Article
- Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer.Breast cancer research and treatment · 2021Article
- Modeling Heterogeneity of Triple-Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Baseline Mutations and Up-Regulation of PI3K-AKT Pathway Serve as Potential Indicators of Lack of Response to Neoadjuvant Chemotherapy in Stage II/III Breast Cancer.Frontiers in oncology · 2021Article
- Clinicopathological Features and Treatment Challenges in Triple Negative Breast Cancer Patients: A Retrospective Cohort Study.Turk patoloji dergisi · 2021Article
- Immunohistological Expression of SOX-10 in Triple-Negative Breast Cancer: A Descriptive Analysis of 113 Samples.International journal of molecular sciences · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mutational profiling of triple-negative breast cancer (TNBC) by whole exome sequencing (WES) yielded a landscape of genomic alterations in this tumor entity. However, the clinical significance of these findings remains enigmatic. Further, integration of WES in routine diagnostics using formalin-fixed paraffin-embedded (FFPE) material is currently not feasible. Therefore, we designed and validated a breast cancer specific gene panel for semiconductor-based sequencing comprising 137 amplicons covering mutational hotspots in 44 genes and applied this panel on a cohort of 104 well-characterized FFPE TNBC with complete clinical follow-up. TP53 mutations were present in more than 80% of cases. PI3K pathway alterations (29.8%) comprising mainly PIK3CA mutations (22.1%) but also mutations and/or amplifications/deletions in other PI3K-associated genes (7.7%) were far more frequently observed, when compared to WES data. Alterations in MAPK signaling genes (8.7%) and cell-cycle regulators (14.4%) were also frequent. Mutational profiles were linked to TNBC subgroups defined by morphology and immunohistochemistry. Alterations in cell-cycle pathway regulators were linked with better overall (p=0.053) but not disease free survival. Taken together, we could demonstrate that breast cancer targeted hotspot sequencing is feasible in a routine setting and yields reliable and clinically meaningful results. Mutational spectra were linked to clinical and immunohistochemically defined parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.